siRNA-mediated suppression of collagen type iv alpha 2 (COL4A2) mRNA inhibits triple-negative breast cancer cell proliferation and migration.
siRNA-mediated suppression of collagen type iv alpha 2 (COL4A2) mRNA inhibits triple-negative breast cancer cell proliferation and migration.
复制标题
siRNA 介导的 iv 型胶原蛋白 α 2 (COL4A2) mRNA 抑制可抑制三阴性乳腺癌细胞增殖和迁移
DOI：
10.18632/oncotarget.13716
复制
发表时间：
2017-01-10
期刊：
影响因子：
--
通讯作者：
Zou C
中科院分区：
文献类型：
--
作者：
JingSong H;Hong G;Yang J;Duo Z;Li F;WeiCai C;XueYing L;YouSheng M;YiWen O;Yue P;Zou C
三阴性乳腺癌（TNBC）比其他乳腺癌亚型更具侵袭性。胶原蛋白IV型α 2（COL 4A 2），基底膜的主要成分，动态影响广泛的生物过程，包括癌症的发病机制和进展。本研究评估了通过慢病毒载体递送的COL 4A 2 siRNA对TNBC细胞的作用。构建COL 4A 2 siRNA慢病毒载体，转染MDA-MB-231和MDA-MB-468细胞。通过RT-PCR定量COL 4A 2 mRNA水平。CCK 8法检测细胞增殖和迁移情况。使用Transwell进行细胞迁移和侵袭测定。流式细胞仪检测细胞凋亡和细胞周期。结果发现，COL 4A 2 siRNA转染MDA-MB-231和MDA-MB-468细胞后，COL 4A 2 mRNA水平显著下调。此外，细胞迁移和增殖显着降低，细胞周期被阻滞。我们的结果表明，COL 4A 2 siRNA显著抑制TNBC细胞的迁移和增殖。抑制COL 4A 2可能成为防治TNBC的新靶点。
Triple-negative breast cancer (TNBC) is more aggressive than other breast cancer subtypes. Collagen type IV alpha 2 (COL4A2), a major component of the basement membrane, dynamically influences a wide range of biological processes, including cancer pathogenesis and progression. This study evaluated the effects of COL4A2 siRNA delivered by lentiviral vector to TNBC cells. COL4A2 siRNA lenti-viral vector was constructed and transfected into MDA-MB-231 and MDA-MB-468 cells. The COL4A2 mRNA levels were quantified by RT-PCR. CCK8 assay was performed to evaluate cell proliferation and migration. Cell migration and invasion assays were carried out using Transwell. Cell apoptosis and cell cycle analyses were conducted using flow cytometric approach. We found that COL4A2 mRNA levels were significantly down-regulated in MDA-MB-231 and MDA-MB-468 cells after transfection with COL4A2 siRNA. Furthermore, cell migration and proliferation were significantly decreased and the cell cycle was arrested. Our results indicated that COL4A2 siRNA significantly suppresses the migration and proliferation of TNBC cells. Inhibition of COL4A2 may be a new target for the prevention and treatment of TNBC.